• Je něco špatně v tomto záznamu ?

Culprit-lesion only versus complete multivessel percutaneous intervention in ST-elevation myocardial infarction: A systematic review and meta-analysis of randomized trials

PA. Villablanca, DF. Briceno, D. Massera, O. Hlinomaz, M. Lombardo, AE. Bortnick, MA. Menegus, RT. Pyo, MJ. Garcia, F. Mookadam, H. Ramakrishna, J. Wiley, M. Faggioni, GD. Dangas,

. 2016 ; 220 (-) : 251-9. [pub] 20160625

Jazyk angličtina Země Nizozemsko

Typ dokumentu časopisecké články, metaanalýza, přehledy

Perzistentní odkaz   https://www.medvik.cz/link/bmc17031605

BACKGROUND: ST-segment elevation myocardial infarction (STEMI) in patients with concomitant multivessel (MV) coronary artery disease (CAD) is associated with poor outcomes. Percutaneous coronary intervention (PCI) of the culprit-lesion only (CLO) as compared with a MV PCI approach to revascularization remains uncertain. Our objective is to gain a better understanding of the efficacy and safety of CLO as compared with MV PCI in patients with STEMI by conducting an updated meta-analysis. METHODS: A comprehensive search of PubMed, CENTRAL, EMBASE, The Cochrane Central Register, the ClinicalTrials.gov Website, and Google Scholar databases of randomized controlled trials (RCTs) was performed. RESULTS: Seven RCTs were included, enrolling a total of 2006 patients. We found that there was a significant reduction in major adverse cardiovascular events (MACE) (OR, 0.62; 95% CI, 0.43-0.90), cardiovascular mortality (OR, 0.46; 95% CI, 0.27-0.80), and repeat revascularization (RRV) (OR, 0.39; 95% CI, 0.30-0.51) favoring MV over the CLO approach for patients undergoing primary PCI. The number needed to treat in order to prevent one CV mortality, RRV, or MACE event is 47, 11, and 16 patients, respectively. No differences were observed between MV vs. CLO PCI for subsequent myocardial infarction (OR, 0.74; 95% CI, 0.40-1.39), all-cause mortality (OR, 0.78; 95% CI, 0.53-1.15), non-cardiovascular mortality (OR, 1.35; 95% CI, 0.74-2.48), all-bleeding events (OR, 0.82; 95% CI, 0.40-1.65), contrast-induced nephropathy (OR, 0.72; 95% CI, 0.33-1.54), and stroke (OR, 1.28; 95% CI, 0.47-3.46). CONCLUSIONS: MV PCI significantly reduces the rate of MACE, CV mortality, and RRV without significant harm as compared to CLO PCI.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc17031605
003      
CZ-PrNML
005      
20171025123914.0
007      
ta
008      
171025s2016 ne f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.ijcard.2016.06.098 $2 doi
035    __
$a (PubMed)27390938
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a ne
100    1_
$a Villablanca, Pedro A $u Division of Cardiovascular Diseases, Montefiore Medical Center/Albert Einstein College of Medicine, New York, USA. Electronic address: pedrovillablanca@hotmail.com.
245    10
$a Culprit-lesion only versus complete multivessel percutaneous intervention in ST-elevation myocardial infarction: A systematic review and meta-analysis of randomized trials / $c PA. Villablanca, DF. Briceno, D. Massera, O. Hlinomaz, M. Lombardo, AE. Bortnick, MA. Menegus, RT. Pyo, MJ. Garcia, F. Mookadam, H. Ramakrishna, J. Wiley, M. Faggioni, GD. Dangas,
520    9_
$a BACKGROUND: ST-segment elevation myocardial infarction (STEMI) in patients with concomitant multivessel (MV) coronary artery disease (CAD) is associated with poor outcomes. Percutaneous coronary intervention (PCI) of the culprit-lesion only (CLO) as compared with a MV PCI approach to revascularization remains uncertain. Our objective is to gain a better understanding of the efficacy and safety of CLO as compared with MV PCI in patients with STEMI by conducting an updated meta-analysis. METHODS: A comprehensive search of PubMed, CENTRAL, EMBASE, The Cochrane Central Register, the ClinicalTrials.gov Website, and Google Scholar databases of randomized controlled trials (RCTs) was performed. RESULTS: Seven RCTs were included, enrolling a total of 2006 patients. We found that there was a significant reduction in major adverse cardiovascular events (MACE) (OR, 0.62; 95% CI, 0.43-0.90), cardiovascular mortality (OR, 0.46; 95% CI, 0.27-0.80), and repeat revascularization (RRV) (OR, 0.39; 95% CI, 0.30-0.51) favoring MV over the CLO approach for patients undergoing primary PCI. The number needed to treat in order to prevent one CV mortality, RRV, or MACE event is 47, 11, and 16 patients, respectively. No differences were observed between MV vs. CLO PCI for subsequent myocardial infarction (OR, 0.74; 95% CI, 0.40-1.39), all-cause mortality (OR, 0.78; 95% CI, 0.53-1.15), non-cardiovascular mortality (OR, 1.35; 95% CI, 0.74-2.48), all-bleeding events (OR, 0.82; 95% CI, 0.40-1.65), contrast-induced nephropathy (OR, 0.72; 95% CI, 0.33-1.54), and stroke (OR, 1.28; 95% CI, 0.47-3.46). CONCLUSIONS: MV PCI significantly reduces the rate of MACE, CV mortality, and RRV without significant harm as compared to CLO PCI.
650    12
$a koronární cévy $x patologie $x chirurgie $7 D003331
650    _2
$a lidé $7 D006801
650    _2
$a revaskularizace myokardu $x metody $7 D009204
650    _2
$a výběr pacientů $7 D018579
650    12
$a koronární angioplastika $x škodlivé účinky $x metody $7 D062645
650    _2
$a randomizované kontrolované studie jako téma $7 D016032
650    12
$a infarkt myokardu s elevacemi ST úseků $x diagnóza $x chirurgie $7 D000072657
650    _2
$a stupeň závažnosti nemoci $7 D012720
650    _2
$a výsledek terapie $7 D016896
655    _2
$a časopisecké články $7 D016428
655    _2
$a metaanalýza $7 D017418
655    _2
$a přehledy $7 D016454
700    1_
$a Briceno, David F $u Division of Cardiovascular Diseases, Montefiore Medical Center/Albert Einstein College of Medicine, New York, USA.
700    1_
$a Massera, Daniele $u Division of Cardiovascular Diseases, Montefiore Medical Center/Albert Einstein College of Medicine, New York, USA.
700    1_
$a Hlinomaz, Ota $u International Clinical Research Center, St. Anne University Hospital, Brno, Czech Republic.
700    1_
$a Lombardo, Marissa $u Department of Internal Medicine, New York-Presbyterian Hospital/Weill Cornell Medical College, New York, NY, USA.
700    1_
$a Bortnick, Anna E $u Division of Cardiovascular Diseases, Montefiore Medical Center/Albert Einstein College of Medicine, New York, USA.
700    1_
$a Menegus, Mark A $u Division of Cardiovascular Diseases, Montefiore Medical Center/Albert Einstein College of Medicine, New York, USA.
700    1_
$a Pyo, Robert T $u Division of Cardiovascular Diseases, Montefiore Medical Center/Albert Einstein College of Medicine, New York, USA.
700    1_
$a Garcia, Mario J $u Division of Cardiovascular Diseases, Montefiore Medical Center/Albert Einstein College of Medicine, New York, USA.
700    1_
$a Mookadam, Farouk $u Cardiovascular Division, Mayo Clinic College of Medicine, Scottsdale, AZ, USA.
700    1_
$a Ramakrishna, Harish $u Division of Cardiovascular and Thoracic Anesthesiology, Mayo Clinic College of Medicine, Scottsdale, AZ, USA.
700    1_
$a Wiley, Jose $u Division of Cardiovascular Diseases, Montefiore Medical Center/Albert Einstein College of Medicine, New York, USA.
700    1_
$a Faggioni, Michela $u The Zena and Michael A. Wiener Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, New York, USA.
700    1_
$a Dangas, George D $u The Zena and Michael A. Wiener Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, New York, USA.
773    0_
$w MED00002299 $t International journal of cardiology $x 1874-1754 $g Roč. 220, č. - (2016), s. 251-9
856    41
$u https://pubmed.ncbi.nlm.nih.gov/27390938 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20171025 $b ABA008
991    __
$a 20171025123956 $b ABA008
999    __
$a ok $b bmc $g 1255198 $s 992632
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2016 $b 220 $c - $d 251-9 $e 20160625 $i 1874-1754 $m International journal of cardiology $n Int J Cardiol $x MED00002299
LZP    __
$a Pubmed-20171025

Najít záznam

Citační ukazatele

Pouze přihlášení uživatelé

Možnosti archivace